Peanut butter cookie? Yes, please!

There’s new hope for kids who have multiple food allergies through a treatment that combines a drug with a food desensitization process, according to a study published Dec. 11 in The Lancet Gastroenterology & Hepatology.

The phase-2 clinical trial of 48 children ages 4 to 15 showed that most kids who received the antibody drug omalizumab while consuming gradually increasing doses of problematic foods could tolerate the foods at the end of the nine-month study, conducted at the Sean N. Parker Center for Allergy and Asthma Research at Stanford.

“This could be a very promising way to decrease the burden of living with food allergies,” says senior author Sharon Chinthrajah, MD, a clinical assistant professor of medicine and pediatrics and director of the center’s Clinical Translational Research Unit.

Additional Reading

Virtual calming

Easing anxiety in young patients using immersive technology

No place to call home

Housing insecurity puts children’s care, treatment at risk